Welcome to our dedicated page for Natera news (Ticker: NTRA), a resource for investors and traders seeking the latest updates and insights on Natera stock.
Natera, Inc. (NASDAQ: NTRA) is a diagnostic and research company in the medical laboratories industry, focused on cell-free DNA testing and precision medicine in oncology, women’s health, and organ health. The Natera news feed on Stock Titan highlights company announcements, clinical data readouts, collaborations, and financial updates that reflect how its testing platforms are used in practice and research.
Recent news has featured advances in molecular residual disease (MRD) testing with Signatera, including new multi-modal AI models that integrate longitudinal circulating tumor DNA, clinical data, digital pathology, and tumor sequencing to refine recurrence risk assessment and outcomes prediction. Natera also reports on large clinical studies and trial analyses in colorectal cancer and breast cancer, where Signatera is used to evaluate MRD, predict treatment response, and support risk stratification.
In women’s health, news items include the launch and validation of Fetal Focus, a single-gene non-invasive prenatal test that uses cell-free DNA from maternal blood to assess inherited conditions when partner testing is not available, as well as updates related to the broader prenatal and carrier screening portfolio. Organ health news may cover the use of Natera’s Prospera test in transplant rejection assessment and related research.
Investors and clinicians can also follow Natera’s announcements about AI collaborations, such as its work with NVIDIA to scale multimodal AI foundation models, and corporate updates including preliminary financial results and participation in healthcare conferences. For those tracking NTRA, this news page provides a centralized view of developments across oncology, women’s health, organ health, and AI-enabled diagnostics.
Natera (NASDAQ: NTRA) has announced positive topline results from the Phase III IMvigor011 trial in muscle-invasive bladder cancer (MIBC), utilizing their Signatera ctDNA test. The trial demonstrated that Signatera-positive patients treated with atezolizumab showed significant improvements in disease-free survival and overall survival.
The study enrolled approximately 760 patients who underwent Signatera testing post-surgery. Notably, patients who remained Signatera-negative showed exceptional outcomes, with 100% overall survival at 12 months and 98% at 18 months. Disease-free survival rates were 92% at 12 months and 88% at 18 months after surgery.
Following these results, Natera will finalize its premarket approval application to the FDA for Signatera as a companion diagnostic for atezolizumab treatment selection in MIBC patients post-cystectomy.
Natera (NASDAQ: NTRA) reported strong Q2 2025 financial results with total revenues of $546.6 million, up 32.2% year-over-year. The company achieved significant milestones including a gross margin of 63.4% and processed 853,100 tests, a 12.2% increase from Q2 2024.
Notable highlights include 50.6% growth in oncology tests to 188,800 units and positive cash flow of $24.3 million. The company raised its 2025 revenue guidance to $2.02-$2.10 billion, an $80 million increase at the midpoint. However, Natera reported a net loss of $100.9 million ($0.74 per share), impacted by legal accruals and stock-based compensation expenses.
Natera (NASDAQ: NTRA) has launched Fetal Focus, a groundbreaking noninvasive prenatal test (NIPT) for inherited conditions. The test addresses a critical gap in prenatal care by screening fetuses directly for five commonly tested genes when the biological father is unavailable for testing.
The launch is backed by initial data from the EXPAND clinical trial, which has enrolled approximately 1,300 participants. In its first milestone readout (n=101), Fetal Focus demonstrated 91% sensitivity and successfully identified all 5 cases of homozygous variants. The test utilizes Natera's proprietary LinkedSNP™ technology and is validated for analyzing genes associated with cystic fibrosis, spinal muscular atrophy, alpha-thalassemia, and beta-hemoglobinopathies including sickle cell disease.
Natera (NASDAQ: NTRA) announced its significant presence at the 2025 World Transplant Congress (WTC) with 16 abstracts, including five oral presentations, showcasing comprehensive data on its Prospera™ test across kidney, heart, and lung transplantation. The presentations highlight results from the Trifecta series of studies and include data from recently published studies in the American Journal of Transplantation, such as the PEDAL clinical trial for kidney transplants and Prospera Heart's performance with Donor Quantity Score (DQS).
Key presentations feature Prospera Kidney's utility in monitoring treatment of chronic antibody-mediated rejection and various studies demonstrating the test's effectiveness across different transplant types. The congress, taking place August 2-6 in San Francisco, represents one of the most extensive collections of data on Natera's Prospera test to date.
Natera (NASDAQ: NTRA), a leader in cell-free DNA and precision medicine, has scheduled its Q2 2025 earnings release for August 7, 2025, after market close. The company will host a conference call and webcast at 1:30 PM PT (4:30 PM ET) to discuss the results.
Investors can join via phone using dial-in numbers 1-888-770-7321 (Domestic) or 1-929-201-7107 (International) with Conference ID 7684785. A webcast will be available at https://events.q4inc.com/attendee/169947359, with a replay accessible on Natera's investor relations website.
Natera (NASDAQ: NTRA) has launched the TEODOR trial, a Phase II randomized controlled trial studying the use of Signatera™ in early-stage breast cancer treatment. The trial aims to identify hormone receptor-positive (HR+), HER2-negative breast cancer patients who could safely avoid chemotherapy before surgery.
The study, sponsored by the Austrian Breast & Colorectal Cancer Study Group (ABCSG), will enroll approximately 250 patients across 15 Austrian sites. Patients who test Signatera-negative and show favorable endocrine sensitivity will be randomized to receive either endocrine therapy or chemotherapy. The trial's primary endpoint focuses on neoadjuvant therapy response, with secondary endpoints including breast cancer recurrence and overall survival.
Natera (NASDAQ: NTRA) announced the publication of its PEDAL study results in the American Journal of Transplantation, demonstrating the prognostic capabilities of its Prospera™ kidney transplant monitoring test. The study, involving 488 kidney transplant recipients across 28 centers, focused on donor-derived cell-free DNA (dd-cfDNA) trends following rejection.
The groundbreaking results showed that patients with low/decreasing Prospera trends had 60x higher odds of positive outcomes after one year and were 13x more likely to have resolving kidney dysfunction. Notably, 97.5% of cases with sustained elevated Prospera trends experienced negative clinical outcomes, highlighting the test's effectiveness in post-rejection risk assessment.
Natera (NASDAQ: NTRA) presented significant clinical data for its tissue-free Latitude™ MRD assay at ESMO GI 2025. The study, part of CIRCULATE-Japan's GALAXY arm, analyzed ~200 patients with over 1,300 plasma samples in resectable stage I-IV colorectal cancer.
Key findings showed excellent clinical performance with 58% sensitivity in post-surgical MRD detection and 81% in surveillance, alongside high specificity (92% patient-level, 97% sample-level). The assay demonstrated strong prognostic value for recurrence risk and effectively predicted adjuvant chemotherapy benefit in high-risk stage II and III patients.
Natera (NASDAQ: NTRA) announced it will present new clinical data for its Signatera™ monitoring technology at the 2025 ESMO GI Congress in Barcelona. The presentations will showcase significant findings across colorectal cancer (CRC) applications.
Key findings include data from over 3,000 CRC patients showing Signatera ctDNA-positive patients were up to 20x more likely to receive curative-intent metastasis-directed therapy compared to Signatera-negative patients. The MD Anderson INTERCEPT study (n=31) demonstrated 100% specificity/PPV and high surveillance sensitivity in rectal cancer patients.
A budget impact model from BUPA insurance revealed a projected 43% reduction in healthcare costs using Signatera-guided adjuvant treatment versus standard care in stage II-III CRC. The company will present six studies at the congress, including validation data on its tissue-free MRD assay and methylation-based biomarkers for colorectal cancer.
FAQ
What is the current stock price of Natera (NTRA)?
What is the market cap of Natera (NTRA)?
